Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 14/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824638 | 1.00 | KCNQ2 (0.56) | KCNQ2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1000318 | 0.84 | KCNQ2 (0.78) | KCNQ2KCNQ3 | |
| SCHEMBL30794725 | 0.84 | KCNQ2 (0.78) | KCNQ2KCNQ3 | |
| SCHEMBL30741269 | 0.83 | KCNQ2 (0.44) | KCNQ2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL19698754 | 0.83 | KCNQ2 (0.44) | KCNQ2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1001116 | 0.81 | KCNQ2 (0.65) | KCNQ2KCNQ3 | |
| SCHEMBL1001114 | 0.81 | KCNQ2 (0.65) | KCNQ2KCNQ3 | |
| SCHEMBL28783965 | 0.80 | KCNQ2 (0.52) | KCNQ2KCNQ3ACACBPHGDH | |
| SCHEMBL1000113 | 0.80 | KCNQ2 (0.72) | KCNQ2KCNQ3 | |
| SCHEMBL1001115 | 0.80 | KCNQ2 (0.61) | KCNQ2KCNQ3PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293911-B2 | Seizure disorders; antiepileptic agents; N-(2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethyl)phenyl)-3,3-dimethylbutanamide for example | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-10-23 | — | — | US | claimed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| US-20240226054-A9 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131000-A1 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993593-B2 | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2015-03-31 | — | — | US | disclosed |
| EP-2061465-B1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INT (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8293911-B2 | Seizure disorders; antiepileptic agents; N-(2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethyl)phenyl)-3,3-dimethylbutanamide for example | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-10-23 | — | — | US | disclosed |
| US-8293911-B2 | Seizure disorders; antiepileptic agents; N-(2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethyl)phenyl)-3,3-dimethylbutanamide for example | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| CN-101563085-A | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators | VERNIER JEAN MICHEL (US) | 2009-10-21 | — | — | CN | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | VALEANT PHARMACEUTICALS NORTH AMERICA (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008024398-A2 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | VALEANT PHARMACEUTICALS INTERNATIONAL (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003850-A1 | DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS | KCNQ2, KCNQ1, KCNQ5 | KCNQ2 1/4885GRIN2D 123/4885GRIN3B 274/4885 |
| US-20080139610-A1 | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators | KCNQ2, KCNQ1, KCNQ5 | KCNQ2 1/4885GRIN2D 148/4885GRIN3B 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.